Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × enzalutamide × Tumor-Agnostic × Clear all

Phase

Phase 2 3 Phase 1 3 Phase 3 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3 Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Oxaliplatin 3 cabazitaxel 2 Radiation 2 vinflunine 1 sugemalimab 1 pembrolizumab 1 osimertinib 1 nedaplatin 1 jinfukang 1 enzalutamide 1 empagliflozin 1 coenzyme Q10 1 camrelizumab 1 beta-Glucans 1 apatinib 1 abiraterone 1 Waiting Lists 1 Tyrosine Kinase Inhibitors 1 Surgical Procedures, Operative 1 Starch 1 Standard of Care 1 Sodium Chloride 1 Sevoflurane 1 Saline Solution, Hypertonic 1 Saline Solution 1 S 1 (combination) 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Pemetrexed 1 Neck Dissection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡